LU AA 47070Alternative Names: Lu AA47070
Latest Information Update: 18 May 2009
At a glance
- Originator Lundbeck A/S
- Mechanism of Action Purinergic P1 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 13 Nov 2007 Phase-I clinical trials in Parkinson's disease in Denmark (unspecified route)